



WOMEN CARE | CHILD CARE | FERTILITY

July 30, 2026

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai - 400051.
Symbol: RAINBOW

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001.
Scrip Code: 543524

Sub: Outcome of Board Meeting held on July 30, 2026.

Dear Sir/ Madam,

This is to inform that pursuant to Regulation 30 and 33 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the SEBI Listing Regulations") and in furtherance to our letter dated July 22, 2026, please take note that the Board of Directors of the Company, in their meeting held today i.e., July 30, 2026, has inter-alia considered and approved the following matters:

1. Financial Results:

The Unaudited Standalone and Consolidated Financial Results ("**Financial Results**") of the Company for the Quarter ended June 30, 2026. A copy of the signed Results along with Limited Review Report issued by the Statutory Auditors M/s. S.R. Batliboi & Associates LLP, Chartered Accountants, are enclosed as **Annexure – A**.

2. Elevation of Mr. Anshuman Jaiswal to Chief Legal Officer and Designation as Senior Management Personnel (SMP):

Pursuant to the recommendation of the Nomination and Remuneration Committee in their meeting held today i.e., July 30, 2026, the Board of Directors approved the elevation of Mr. Anshuman Jaiswal from the position of Group Head – Legal to Chief Legal Officer. Consequent to such elevation, the Board also designated him as a Senior Management Personnel (SMP) of the Company with immediate effect, in accordance with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad- 500034, Telangana
CIN:L85110TG1998PLC029914

Corporate Office: 8-2-19/1/A, Daulet Arcade, Road No. 11, Banjara Hills, Hyderabad- 500034, Telangana

info@rainbowhospitals.in 1800 2122 www.rainbowhospitals.in



WOMEN CARE | CHILD CARE | FERTILITY

The requisite disclosure as per Regulation 30 of the SEBI Listing Regulations read with Schedule III thereto and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as **Annexure – B**.

The Board Meeting commenced at 12:30 P.M and concluded at 4:00 P.M.

This is for your information and record.

Thanking You,

Yours Faithfully,

For **Rainbow Children's Medicare Limited**

Shreya Mitra

Company Secretary and Compliance Officer

Encl.: As above

Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad- 500034, Telangana

CIN:L85110TG1998PLC029914

 **Corporate Office:** 8-2-19/1/A, Daulet Arcade, Road No. 11, Banjara Hills, Hyderabad- 500034, Telangana

 info@rainbowhospitals.in

 1800 2122

 www.rainbowhospitals.in

S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

THE SKYVIEW 10
18th Floor, "NORTH LOBBY"
Survey No. 83/1, Raidurgam
Hyderabad - 500 032, India
Tel : +91 40 6141 6000

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Rainbow Children's Medicare Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Rainbow Children's Medicare Limited (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

Atin Bhargava
Per Atin Bhargava
Partner

Membership No.: 504777



UDIN: 26504777E0PVQQ4899

Place : Hyderabad

Date : July 30, 2026

Rainbow Children's Medicare Limited

CIN: L85110TG1998PLC029914

Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034

Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in

Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2026

(Rs. in Million except per share data)

Particulars	Quarter ended			Year ended
	30 June 2026	31 March 2026	30 June 2025	31 March 2026
	Unaudited	Audited	Unaudited	Audited
1. Income				
a. Revenue from operations	4,105.47	4,080.64	3,347.48	15,456.60
b. Other income	127.57	52.40	192.85	434.54
Total income	4,233.04	4,133.04	3,540.33	15,891.14
2. Expenses				
a. Cost of materials consumed	546.85	485.72	439.50	1,996.69
b. Employee benefits expense	599.08	566.16	492.36	2,123.93
c. Finance costs	192.49	185.24	173.93	713.96
d. Depreciation and amortisation expense	376.26	356.52	325.93	1,362.61
e. Professional fees to doctors	1,087.30	986.19	867.81	3,770.65
f. Other expenses	725.65	753.21	552.60	2,566.76
Total expenses	3,527.63	3,333.04	2,852.13	12,534.60
3. Profit before exceptional items and tax [1-2]	705.41	800.00	688.20	3,356.54
4. Exceptional items	-	15.39	-	15.39
5. Profit before tax [3-4]	705.41	784.61	688.20	3,341.15
6. Tax expenses				
a. Current tax	189.59	230.37	168.65	917.83
b. Deferred tax expense / (credit)	(11.24)	(38.81)	5.81	(73.38)
c. Adjustment of tax relating to earlier periods	-	-	(3.46)	(3.46)
Total tax expense	178.35	191.56	171.00	840.99
7. Profit after tax [5-6]	527.06	593.05	517.20	2,500.16
8. Other comprehensive income				
Items that will not be reclassified subsequently to the Statement of Profit or Loss				
a. Re-measurement (loss) / gain on defined benefit obligation	(2.21)	(6.67)	(0.72)	(8.83)
b. Income tax effect	0.56	1.68	0.18	2.22
Other comprehensive income (net of tax)	(1.65)	(4.99)	(0.54)	(6.61)
9. Total comprehensive income [7+8]	525.41	588.06	516.66	2,493.55
10. Paid-up equity share capital (Face value of Rs. 10 each)	1,015.66	1,015.59	1,015.52	1,015.59
11. Other equity				15,874.98
12. Earning per share (Face value of Rs.10 each)				
a. Basic (Rs)	5.20	5.85	5.09	24.62
b. Diluted (Rs)	5.20	5.85	5.09	24.62
	(Not annualised)	(Not annualised)	(Not annualised)	



Notes :

- 1 The above statement of unaudited standalone financial results of Rainbow Children's Medicare Limited ("the Company"), which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 30
- 2 The standalone figures for the fourth quarter ended 31 March 2026 are the balancing figures between published audited figures in respect of the full previous financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year.
- 3 Final dividend for the financial year 2025-26 of Rs. 3.50 per Equity Share of Rs. 10 each aggregating to Rs.355.48 million was approved by the shareholders at the 28th Annual General Meeting held on 29 July 2026 and the same was paid on 29 July 2026.
- 4 Pursuant to the resolutions passed by the Board of Directors on 09 February 2025 and by the Shareholders on 02 April 2025, the Company approved 'The Rainbow Children's Medicare Limited - Employee Stock Option Scheme 2025 ("ESOP 2025") in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBEB SE Regulations"). The ESOP 2025 is for issue of employee stock options to eligible employees, which may result in an issuance of a maximum number of 1,015,000 Equity Shares. Upon exercise and payment of the exercise price, an option holder will be entitled to be allotted one equity share per employee stock option.
The Nomination and Remuneration Committee ("NRC") of the Company in its meeting held on 23 May 2026, granted 267,550 Stock options under the ESOP 2025 to its eligible employees which shall be exercisable into 267,550 equity shares having face value of Rs.10 each fully paid-up. The Exercise price per stock option shall be determined at a discount of not more than 20% on the latest available closing price of the Company's equity shares on the National Stock Exchange of India Limited, being the stock exchange with the highest trading volume, as on 22 May 2026 i.e., the trading day immediately preceding the date on which the grant of options was approved by the NRC. The Stock options shall vest after the minimum vesting period of 1 year and not later than the maximum period of 10 years from the date of grant. The vested Stock options shall be exercisable within a period of maximum of 2 years from the date of each vesting.
- 5 The Company has allotted 7,483 equity shares of Rs. 10 each, consequent to the exercise of the stock options by an eligible employee of the Company under the Rainbow Children's Medicare Limited - Employee Stock Unit Plan 2023 ("Stock Unit Plan 2023"). The allotment has been approved by the Nomination and Remuneration committee on 25 June 2026.
- 6 Subsequent to the quarter end, the Company has executed the definitive transaction documents, including a Shareholders' Agreement ("Transaction Documents"), in connection with the proposed capacity addition through development of a new children and women's hospital at Malad, Mumbai through its wholly owned subsidiary, Rainbow Women & Children's Hospital Private Limited ("RWCHPL") and the transaction is expected to be completed in the quarter ended 30 September 2026.
- 7 Subsequent to the quarter end, the Company has executed a Partnership Interest and Contribution Transfer Agreement ("PCTA") with the existing partners of Super Prime Medical Care LLP ("LLP"), in connection with the proposed acquisition by the Company of 64% (Sixty Four Percent) partnership interest for an aggregate consideration of Rs. 198 million. Upon completion of the proposed transaction, the LLP shall become a subsidiary of the Company. The proposed transaction is intended to acquire a running children's hospital at Nellore, Andhra Pradesh. The acquisition is expected to be completed in the quarter ended 30 September 2026.
- 8 The Company is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operations of the Company are concentrated in India, and hence, the Company is considered to operate only in one geographical segment.
- 9 The unaudited standalone financial results for the quarter ended 30 June 2026, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in).

for and on behalf of the Board of Directors of
Rainbow Children's Medicare Limited



Dr. Ramesh Kancharla
Chairman and Managing Director
DIN: 00212270

Place : Hyderabad
Date : 30 July 2026

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Rainbow Children's Medicare Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Rainbow Children's Medicare Limited (the "Holding Company"), its subsidiaries and other consolidating entity (the Holding Company, its subsidiaries and other consolidating entity together referred to as "the Group") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.


4. The Statement includes the results of the following entities:

Holding Company:
Rainbow Children's Medicare Limited

Subsidiaries:

- a. Rainbow Speciality Hospitals Private Limited
- b. Rosewalk Healthcare Private Limited
- c. Rainbow C R O Private Limited
- d. Rainbow Fertility Private Limited
- e. Rainbow Children's Hospital Private Limited
- f. Rainbow Woman & Children's Hospital Private Limited
- g. Prashanthi Medicare Private Limited (with effect from July 01, 2025)
- h. Pratiksha Women & Child Care Hospital Private Limited (with effect from August 18, 2025)

Other Consolidating Entity:
Rainbow Children's Hospital Foundation



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of 4 subsidiaries and 1 other consolidating entity, whose interim financial results and other financial information reflect total revenues of Rs 0.02 million, total net profit after tax of Rs 1.16 million, total comprehensive income of Rs 1.16 million, for the quarter ended June 30, 2026.


The unaudited interim financial results and other unaudited financial information of the these subsidiaries and other consolidating entity have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries and other consolidating entity, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial information and financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the financial results/financial information certified by the Management.

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004


per Atin Bhargava
Partner

Membership No.: 504777



UDIN: 26504777WXUUUV7821

Place: Hyderabad

Date: July 30, 2026

Rainbow Children's Medicare Limited				
CIN: L85110TG1998PLC029914				
Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034				
Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in				
Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2026				
(Rs. in Million except per share data)				
Particulars	Quarter ended		Year ended	
	30 June 2026	31 March 2026	30 June 2025	31 March 2026
	Unaudited	Audited	Unaudited	Audited
1. Income				
a. Revenue from operations	4,699.85	4,599.01	3,529.29	17,030.77
b. Other income	127.10	50.64	200.16	437.88
Total income	4,826.95	4,649.65	3,729.45	17,468.65
2. Expenses				
a. Cost of materials consumed	645.42	569.83	474.98	2,270.29
b. Employee benefits expense	668.50	630.70	516.20	2,335.30
c. Finance costs	212.05	204.95	180.78	776.17
d. Depreciation and amortisation expense	421.97	409.42	341.87	1,505.70
e. Professional fees to doctors	1,238.19	1,126.71	917.58	4,188.10
f. Other expenses	801.29	824.74	584.30	2,795.41
Total expenses	3,987.42	3,766.35	3,015.71	13,870.97
3. Profit before exceptional items and tax [1-2]	839.53	883.30	713.74	3,597.68
4. Exceptional items	-	15.39	-	15.39
5. Profit before tax [3-4]	839.53	867.91	713.74	3,582.29
6. Tax expenses				
a. Current tax	222.84	258.34	174.82	964.79
b. Deferred tax expense/(credit)	(8.71)	(172.61)	4.33	(194.48)
c. Adjustment of tax relating to earlier periods	-	(0.00)	(3.46)	(3.46)
Total tax expense	214.13	85.73	175.69	766.85
7. Profit after tax [5-6]	625.40	782.18	538.05	2,815.44
8. Other comprehensive income				
Items that will not be reclassified subsequently to the Statement of Profit or Loss				
a. Re-measurement (loss)/gain on defined benefit obligation	(2.40)	(8.85)	(0.24)	(9.58)
b. Income tax effect	0.61	2.13	0.09	2.41
Other comprehensive income (net of tax)	(1.79)	(6.72)	(0.15)	(7.17)
9. Total comprehensive income [7+8]	623.61	775.46	537.90	2,808.27
Profit after tax attributable to				
Owners of the Company	605.72	770.43	534.99	2,783.23
Non-controlling interests	19.68	11.75	3.06	32.21
Profit after tax	625.40	782.18	538.05	2,815.44
Other comprehensive income attributable to				
Owners of the Company	(1.78)	(6.54)	(0.21)	(7.12)
Non-controlling interests	(0.01)	(0.17)	0.06	(0.05)
Other comprehensive income	(1.79)	(6.71)	(0.15)	(7.17)
Total comprehensive income attributable to				
Owners of the Company	603.94	763.89	534.78	2,776.11
Non-controlling interests	19.67	11.58	3.12	32.16
Total comprehensive income	623.61	775.47	537.90	2,808.27
10. Paid-up equity share capital (Face value of Rs. 10 each)	1,015.66	1,015.59	1,015.52	1,015.59
11. Other equity				15,465.15
12. Earning per share (Face value of Rs.10 each)				
a. Basic (Rs)	5.97	7.59	5.27	27.41
b. Diluted (Rs)	5.97	7.59	5.27	27.41
	(Not annualised)	(Not annualised)	(Not annualised)	



Notes :

- 1 The above statement of unaudited consolidated financial results of Rainbow Children's Medicare Limited ("the Company"), its subsidiaries and other consolidating entity (the Company, its subsidiaries and other consolidating entity together referred to as "the Group") which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 30 July 2026.
- 2 The consolidated figures for the fourth quarter ended 31 March 2026 are the balancing figures between published audited figures in respect of the full previous financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year.
- 3 Final dividend for the financial year 2025-26 of Rs. 3.50 per Equity Share of Rs. 10 each aggregating to Rs.355.48 million was approved by the shareholders at the 28th Annual General Meeting held on 29 July 2026 and the same was paid on 29 July 2026.
- 4 Pursuant to the resolutions passed by the Board of Directors on 09 February 2025 and by the Shareholders on 02 April 2025, the Company approved 'The Rainbow Children's Medicare Limited - Employee Stock Option Scheme 2025 ("ESOP 2025") in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBEB SE Regulations"). The ESOP 2025 is for issue of employee stock options to eligible employees, which may result in an issuance of a maximum number of 1,015,000 Equity Shares. Upon exercise and payment of the exercise price, an option holder will be entitled to be allotted one equity share per employee stock option.
The Nomination and Remuneration Committee ("NRC") of the Company in its meeting held on 23 May 2026, granted 267,550 Stock options under the ESOP 2025 to its eligible employees which shall be exercisable into 267,550 equity shares having face value of Rs.10 each fully paid-up. The Exercise price per stock option shall be determined at a discount of not more than 20% on the latest available closing price of the Company's equity shares on the National Stock Exchange of India Limited, being the stock exchange with the highest trading volume, as on 22 May 2026 i.e., the trading day immediately preceding the date on which the grant of options was approved by the NRC. The Stock options shall vest after the minimum vesting period of 1 year and not later than the maximum period of 10 years from the date of grant. The vested Stock options shall be exercisable within a period of maximum of 2 years from the date of each vesting.
- 5 The Company has allotted 7,483 equity shares of Rs. 10 each, consequent to the exercise of the stock options by an eligible employee of the Company under the Rainbow Children's Medicare Limited - Employee Stock Unit Plan 2023 ("Stock Unit Plan 2023"). The allotment has been approved by the Nomination and Remuneration committee on 25 June 2026.
- 6 Subsequent to the quarter end, the Company has executed the definitive transaction documents, including a Shareholders' Agreement ("Transaction Documents"), in connection with the proposed capacity addition through development of a new children and women's hospital at Malad, Mumbai through its wholly owned subsidiary, Rainbow Women & Children's Hospital Private Limited ("RWCHPL") and the transaction is expected to be completed in the quarter ended 30 September 2026.
- 7 Subsequent to the quarter end, the Company has executed a Partnership Interest and Contribution Transfer Agreement ("PCTA") with the existing partners of Super Prime Medical Care LLP ("LLP"), in connection with the proposed acquisition by the Company of 64% (Sixty Four Percent) partnership interest for an aggregate consideration of Rs. 198 million. Upon completion of the proposed transaction, the LLP shall become a subsidiary of the Company. The proposed transaction is intended to acquire a running children's hospital at Nellore, Andhra Pradesh. The acquisition is expected to be completed in the quarter ended 30 September 2026.
- 8 The Group is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operations of the group are concentrated in India, and hence, the group is considered to operate only in one geographical segment.
- 9 The consolidated financial results for the quarter ended 30 June 2026, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in).
- 10 The unaudited consolidated financial results include the financial results of Rainbow Children's Medicare Limited and the financial results of its subsidiaries, Rainbow C R O Private Limited, Rainbow Fertility Private Limited, Rainbow Women & Children's Hospital Private Limited, Rainbow Speciality Hospitals Private Limited, Rosewalk Healthcare Private Limited, Rainbow Children's Hospital Private Limited, Prashanthi Medicare Private Limited, Pratiksha Women & Child Care Hospital Private Limited and its other consolidating entity, Rainbow Children's Hospital Foundation.

for and on behalf of the Board of Directors of
Rainbow Children's Medicare Limited




Dr. Ramesh Kancharla
Chairman and Managing Director
DIN: 00212270

Place : Hyderabad
Date : 30 July 2026

Annexure – B

S. No	Particulars	Mr. Anshuman Jaiswal
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Elevation of Mr. Anshuman Jaiswal from the position of Group Head – Legal to Chief Legal Officer. Consequent to such elevation, the Board has also designated him as a Senior Management Personnel (SMP).
2.	Date of appointment & term of appointment.	July 30, 2026
3.	Brief Profile	Mr. Anshuman Jaiswal is an India-qualified corporate counsel with over two decades of experience across law firms and in-house roles. Anshuman is from the first batch of NALSAR University of Law, Hyderabad, and graduated in 2003 with six gold medals. Prior engagements include Partnerships at Amarchand Mangaldas and Cyril Amarchand Mangaldas, and Senior Vice President at GIC-controlled Greenko Group. His experience spans strategic investments and acquisitions, capital markets (Indian and overseas listings; equity, derivative and debt), financing, corporate advisory, commercial contracting, restructuring and disputes.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad- 500034, Telangana

CIN:L85110TG1998PLC029914

Corporate Office: 8-2-19/1/A, Daulet Arcade, Road No. 11, Banjara Hills, Hyderabad- 500034, Telangana

info@rainbowhospitals.in

1800 2122

www.rainbowhospitals.in